Open-Label, Randomized, Multicenter, Multiple-Dose, Active Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension
Phase of Trial: Phase III
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Dimethyl fumarate (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONNECT
- Sponsors Biogen
- 10 Jun 2017 Biomarkers information updated
- 07 Jul 2016 Planned End Date changed from 1 Sep 2020 to 1 Jan 2025.
- 07 Jul 2016 Planned primary completion date changed from 1 Sep 2020 to 1 May 2020.